Another RD leaves

Quote

Look no further than the VP of sales and you know why everyone good leaves. And now this new CCO doesn’t seem to know what he’s doing, so he’s out in the field with us asking a million questions.
 


anonymous said:
Look no further than the VP of sales and you know why everyone good leaves. And now this new CCO doesn’t seem to know what he’s doing, so he’s out in the field with us asking a million questions.
Click to expand...
VP of sales has no idea what he is doing. Look at his background, has never ran a sales organization. Also, have never seen him sell a single vial. Glad the CCO is going out into the field. Time to find a real VP of sales.
 


When I started we were told EXPAREL would sell iitself.
Low hanging fruit was orthopedics, gained vigorous growth. The key ortho speaker, Bill Lanzer, was speaking all over the country. Interestingly, Lanzer never used EXPAREL. I kid you not. Insane.
Pacira, in its infinite wisdom, then consciously ignored these same early- adopting orthopods. Again, insane.
An internal battle then occurred when Medical Affairs claimed to have driven sales growth. So much for the firewall between sales and MA.
Sales growth was the result of speaker programs hosted by well compensated physicians. Definitely Quid Pro Quo. If you speaks for us we will pay you to speak, you have to use the product.
This strategy peaked. Then Kaplan left. Sluby was ambushed by McLoughlin, Murphy, and Reiser. So much for first AA executive. Depuy-Synthes partnership. led by McLoughlin, was a titanic disaster. Many DPS rep making 4x more than TBMs while doing absolutely nothing.
Some really successful and effective RDs found greener pastures, these departures were back-filled with terrible TBMs. Many of these promoted to quench HR complaints. Glenn & Van were ineffective; useless.
All the time Rich Kane, VP of HR, fostered a mysogynistic, hostile work environment. Just what a company needs.
Failed acquisitions, failed endpoints on studies, suits by investors, etc. Only reinforced the ineptness of senior leadership.
Finally Stack leaves. Lee doesn’t stand a chance. Frankly, no one knows their ass from a hole in the ground.

*Sorry, so much more. Just got tired.
 




anonymous said:
Correction, Rich Kahr.
Click to expand...

anonymous said:
When I started we were told EXPAREL would sell iitself.
Low hanging fruit was orthopedics, gained vigorous growth. The key ortho speaker, Bill Lanzer, was speaking all over the country. Interestingly, Lanzer never used EXPAREL. I kid you not. Insane.
Pacira, in its infinite wisdom, then consciously ignored these same early- adopting orthopods. Again, insane.
An internal battle then occurred when Medical Affairs claimed to have driven sales growth. So much for the firewall between sales and MA.
Sales growth was the result of speaker programs hosted by well compensated physicians. Definitely Quid Pro Quo. If you speaks for us we will pay you to speak, you have to use the product.
This strategy peaked. Then Kaplan left. Sluby was ambushed by McLoughlin, Murphy, and Reiser. So much for first AA executive. Depuy-Synthes partnership. led by McLoughlin, was a titanic disaster. Many DPS rep making 4x more than TBMs while doing absolutely nothing.
Some really successful and effective RDs found greener pastures, these departures were back-filled with terrible TBMs. Many of these promoted to quench HR complaints. Glenn & Van were ineffective; useless.
All the time Rich Kane, VP of HR, fostered a mysogynistic, hostile work environment. Just what a company needs.
Failed acquisitions, failed endpoints on studies, suits by investors, etc. Only reinforced the ineptness of senior leadership.
Finally Stack leaves. Lee doesn’t stand a chance. Frankly, no one knows their ass from a hole in the ground.

*Sorry, so much more. Just got tired.
Click to expand...
Very sad to see an outstanding product that could have changed pain management for billions of patients worldwide be destroyed by a bunch of phony executives who only cared about paying themselves. All you have to do is look at the stock price and that tells you the story.
 




Above has some facts correct and many incorrect. It’s the same disgruntled ranting we’ve seen on here for years. All old news that has zero relevance now. Get a life, anyone who defends Sluby has no credibility.
Today’s Pacira is figuring itself out. There’s still some dead wood that needs to go. There’s new leadership that will be exposed as incompetent.
We have a $700,000,000 a year product! Mic drop
 




anonymous said:
RD’s that are leaving are smart. Pacira needs to look at the ones that have been around to long. Start with the ones who have HR wrap sheet, JS, LL, JS…….need to clean house Pacira!
Click to expand...
I heard there are some horrible RDs. And rumor has it the LL may be the worst. Why would people even consider this company?
 


anonymous said:
I heard there are some horrible RDs. And rumor has it the LL may be the worst. Why would people even consider this company?
Click to expand...
I heard from a friend that works there a great rep left because of the RD and she ended up coming back because they promised she would not report to the RD. Why are the reps always the ones that leave or get let go and not their managers??
 




anonymous said:
Above has some facts correct and many incorrect. It’s the same disgruntled ranting we’ve seen on here for years. All old news that has zero relevance now. Get a life, anyone who defends Sluby has no credibility.
Today’s Pacira is figuring itself out. There’s still some dead wood that needs to go. There’s new leadership that will be exposed as incompetent.
We have a $700,000,000 a year product! Mic drop
Click to expand...
There’s been no solution to the same problems. That’s why there’s “the same disgruntled ranting we’ve seen on here for years.” Great insight, Justin.
 


anonymous said:
Above has some facts correct and many incorrect. It’s the same disgruntled ranting we’ve seen on here for years. All old news that has zero relevance now. Get a life, anyone who defends Sluby has no credibility.
Today’s Pacira is figuring itself out. There’s still some dead wood that needs to go. There’s new leadership that will be exposed as incompetent.
We have a $700,000,000 a year product! Mic drop
Click to expand...
Pacira has a lot of figuring out to do. Can’t get rid of bad actors because HR is horrible, there is no pipeline of talent and Glassdoor ratings keep dropping so good outside talent won’t join. Also FL genius idea of marketing to patients isn’t going to work and going to waste more money. Patients don’t tell their surgeons what to do you. Could you imagine a random patient tells your knee doctor, “I want EXPAREL” and the md saying we use something else it’s not on formulary. What would the patient say no I want EXPAREL you need to get it on formulary? Lastly why buy another company when you can’t even grow the two other companies you bought…Pacira is a one trick pony barely hanging on to growth…the stock reflects that.
 



Write your reply...
Top Bottom
Back
Quote